Virus-, host-, immune-based targets for COVID-19 therapy.

A clinical case with pneumonia-like symptoms caused by SARS-CoV-2 was first recorded in the Wuhan city of Hubei province, China [1]. Virus-based targets S protein being the crucial protein facilitating the SARS-CoV-2 entry into the host has been preferred as a potential therapeutic target of interests as it could be spliced into two individual peptides by the furin-like proteases [5]. While, with the non-endosomal entry, the host-dependent transmembrane serine protease 2 (TMPRSS2) paves the SARS-CoV invasion by cleaving its S-glycoprotein [7]. [Extracted from the article]